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ORIGINAL ARTICLE
Beyond the stigma of methadone  
maintenance treatment: 
Neurocognitive recovery in individuals with opiate use disorders 
Kristian Sant, Aloisia Camilleri, Anthony Dimech   
BACKGROUND 
Studies of cognitive functioning in drug addiction have shown 
consistent impairments among substance dependent populations. 
Several attempts to highlight the neurocognitive recovery of former 
opioid dependent individuals who are stabilised on methadone, have 
resulted in contradictory conclusions. The aim of this study is to 
compare the cognitive function of recovering opioid dependent 
individuals on methadone maintenance treatment to those who are 
not on methadone treatment, relative to healthy controls.  
METHODS 
The Montreal Cognitive Assessment Tool was administered to three 
groups of participants: 22 former opioid dependents receiving 
methadone maintenance treatment, 21 former opioid dependents 
withdrawn from all opiates and 22 healthy controls without a history 
of illicit substance dependence. The specific cognitive domains 
tested include executive function, visuospatial skills, naming, 
attention, language, abstraction, delayed recall and orientation. 
RESULTS 
Visuospatial skills and executive function were significantly improved 
with methadone. The language domain appears to be significantly 
impaired in both opioid dependent groups with a strong negative 
correlation to the duration of dependency. Participants who had 
stopped methadone were significantly impaired in all other aspects 
of cognition tested apart from naming and orientation when 
compared to healthy controls. Participants on methadone did not 
significantly differ in the other areas of cognition when compared to 
controls. 
CONCLUSIONS 
Methadone treatment appears to be associated with an 
improvement in cognitive function in opioid dependent individuals. 
Thus, methadone may facilitate public health by ensuring compliance 
of opioid dependent individuals to their treatment plan with fewer 
relapse rates and mitigation of risky behaviours.  
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INTRODUCTION 
The pivotal notions conveyed by prominent 
medical definitions of substance addiction 
primarily include the persistent engagement 
in drug-related behaviours mirroring 
impaired control in the face of devastating 
repercussions.1-2 Underlying pathological 
brain changes, which are put forth as induced 
by the repeated exposure to psychoactive 
substances, are manifested most noticeably 
through tolerance to drug effects and 
withdrawal symptoms on abrupt cessation. 
Most importantly, altered intellectual 
function, disrupting reward processing and 
executive tasks is driven primarily by the 
neurotoxic drug effects.3  
The reported prevalence of cognitive 
impairment in substance use disorder (SUD) 
varies widely between 30-80%.4-7 The overall 
impact of various drugs on cognition also 
varies, but research indicates that individuals 
with SUD have alterations in brain structures 
including the striatum, prefrontal cortex, 
amygdala, and hippocampus.8-10 Exposure to 
substances including heroin which dates 
back to the neuro-maturation stages of 
adolescence is particularly worrisome in this 
regard.11 
The brain regions and neural processes that 
underlie addiction overlap extensively with 
those that support cognitive functions; 
including executive functioning, learning, 
memory, attention, reasoning, decision-
making and impulse control.12 Cognitive 
shifts that drive continued drug use through 
maladaptive learning hinder the adoption of 
alternative behaviours that promote 
abstinence. This leads to poorer treatment 
outcomes through decreased treatment 
adherence, engagement and readiness to 
change.13-14  
The evidence surrounding the extent of 
neurocognitive recovery with methadone 
maintenance treatment (MMT) for opioid 
disorders (OD) is often contradictory. Some 
have reported persistent impairments, while 
others have described comparable cognitive 
performance to that of healthy controls (HC) 
who have never abused any type of illicit 
substance.15-16 Others found no significant 
deterioration in the cognitive performance 
of patients on long-term and relatively high 
dose MMT.17 Nonetheless, MMT is 
associated with amelioration in specific 
cognitive domains amongst patients with 
OD, especially executive function and visuo-
construction.18 After two months of MMT, 
improvements in verbal learning and 
memory, visuospatial memory, and 
psychomotor speed, were recorded in a 
sample of persons with OD.19  
When OD individuals engage with MMT, 
treatment retention is high and a significant 
proportion manage to reduce or stop opioid 
use.20 It has been shown that MMT is many 
times more cost-effective than no treatment 
and the extent to which these improved 
outcomes are underpinned by a mechanism 
of cognitive enhancement is debatable.21 
MMT was associated with intact cognitive 
control in OD individuals, mitigation of  risky 
behaviours and enhanced behavioural 
learning.22 On the other hand, OD individuals 
are at an increased risk of relapse of illicit 
opioid use after methadone detoxification.23  
A Cochrane review uncovered the 
superiority of MMT over non-opioid 
interventions, questioning the one-size-fits-
all philosophy of traditional psychosocial 
interventions to OD.24 The insistence on 
methadone cessation is not without risks 
and can precipitate adverse effects including 
elevated relapse and death rates.25-27 
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Unfortunately the integration of MMT in 
therapeutic communities is not mainstream, 
despite reported effectiveness.28 The impact 
of an intervention with documented harm 
reduction benefits such as MMT on cognitive 
function is paramount, especially when one 
takes an overall view of the process of 
recovery which warrants the mobilisation of 
cognitive skills to confront the various 
individual challenges to reestablish a 
meaningful existence. 
Methodological differences and various 
study limitations such as a small sample size 
and a vast array of confounding factors 
(polysubstance abuse, severity and duration 
of OD, attained educational level, duration 
of stability on methadone and abstinence 
from illicit drugs, methadone dose and the 
presence of neuropsychiatric conditions) 
make it difficult to conclusively determine 
whether methadone offers cognitive 
stability.29  
The goal of the current study is to 
investigate the cognitive performance of 
individuals who have gained stability on 
MMT and attained abstinence in comparison 
to those who were previously on the same 
treatment, underwent detoxification and 
are currently abstinent for at least 1 month. 
A third matched group with no SUD history is 
included. To our knowledge previous 
comparisons of cognitive function were not 
carried out specifically on these groups with 
the aim of deciphering whether it is 
methadone detoxification or maintenance 
that impacts best on cognitive performance, 
in a way that fosters the ability to cope with 
further rehabilitation and the challenges of 
life in general.  
The Montreal Cognitive Assessment Tool 
(MoCA) is a 10-minute 30-point test with 
known sensitivity to mild cognitive 
impairment and which has effectively 
detected cognitive deficits in SUD patients.17 
It is quick, easy to administer and also sheds 
light on the specific neural circuitry 
underlying habitual behaviour in addiction. 
In accordance with previous literature 
reports, we hypothesised that both groups 
of former opiate users would perform worse 
than the control group. We additionally 
hypothesised that MMT stabilises 
neurocognitive function in those individuals 
who abstain from the illicit drugs. OD 
individuals who stabilise on methadone are 
expected to have a better neurocognitive 
function than those who come off 
methadone to access traditional 
rehabilitation programmes. 
MATERIALS AND METHODS 
Healthy male and female subjects, 18-50 
years of age, were selected for inclusion in 
one of three groups based on their opioid 
use history: (1) Individuals having a history of 
OD who are stable on MMT; (2) Individuals 
having a history of OD who were on 
methadone but have undergone methadone 
detoxification (NOMT); and (3) HC 
individuals without a history of opioid or 
other illicit substance dependence, matched 
for gender, district and educational level. For 
inclusion in the MMT and NOMT groups, 
participants were required to fulfil a former 
DSM-5 diagnosis of OD and to have been 
free of any illicit drug for at least one month, 
confirmed through negative urine toxicology 
screening tests (excluding methadone in the 
MMT group).   
The MMT participants were recruited either 
from (i) Mount Carmel Psychiatric Hospital, 
whereby, patients had been admitted and 
stabilised on methadone for at least one 
month, (ii) Substance Misuse Outpatients 
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Clinic, whereby patients were on a stable 
methadone dose or (iii) Substance Misuse 
Outpatients Clinic, whereby patients had 
been granted the Take Home Methadone 
Policy. 
The NOMT participants were recruited from 
a residential drug rehabilitation program 
(Caritas or Sedqa). The inclusion criteria for 
this group consisted of prior MMT, followed 
by gradual methadone detoxification to 
complete abstinence. All NOMT participants 
required to be methadone-free for a 
minimum of one month. 
The HC population participants were 
recruited from Bormla public health centre 
general practitioner’s clinic attendees. A 
southern harbour health centre was chosen 
whilst attempting to select a healthy sample 
resembling the OD sample as much as 
possible, in accordance with the National 
Audit Office Report (2012) which stated that 
the district that registers the highest 
proportion of individuals with SUD is the 
southern harbour region.30 Patients or their 
relatives who presented with a minor health 
complaint which was not psychiatric in origin 
and who had never used any type of illicit 
substance, underwent cognitive testing.   
Exclusionary criteria for all participants were 
any current Axis I diagnosis (other than OD 
for the MMT and NOMT groups, and nicotine 
dependence for all groups), history of head 
trauma, brain injury, neurological disease, 
substance-induced psychoses, epileptic 
seizures, human immunodeficiency virus 
infection, pregnancy, or any other medical  
condition which might affect the individual’s 
cognitive function. Individuals who were 
administered any opioid replacement 
strategy e.g. Buprenorphine / DHC / 
Tramadol / Codeine were excluded from this 
study. Those who refused to give urines 
were automatically excluded from this study. 
Routine screening tested the detection of 
amphetamines, cocaine, cannabinoids, 
methadone and opiates. Exclusion criteria 
for control subjects included current or past 
history of any illicit substance. 
Initial screening for the MMT group was 
done through the Substance Misuse unit 
database, whereby eligible patients were 
contacted and informed about this current 
study. Similarly, potential NOMT participants 
who were enrolled in Caritas and Sedqa 
residential drug rehabilitation programs and 
expressed interest in participating were 
invited for a face-to-face interview, 
consisting of the Beck’s Depression and 
Anxiety Inventories. Only those participants 
who did not suffer from any psychiatric 
condition which might impair cognitive 
function were selected and assessed with 
the MoCA. All interviews were conducted by 
the same clinician to eliminate any observer 
or systematic bias. No sampling method was 
used to recruit participants as all available 
patients who were benefiting from these 
addiction services throughout April-
September 2017 and who met inclusion and 
exclusion criteria were recruited. In all, 22 
participants satisfied the criteria for 
inclusion in the MMT group, 21 participants 
were included in the NOMT group and 22 HC 
participants were enrolled out of their own 
free will. This study was reviewed and 
approved by the Malta Health Ethics 
Committee Board and the Foundation for 
Social Welfare Services Ethics Committee. 
A naturalistic cross-sectional comparative 
design was employed for this study. 
Randomization of the participants was not 
possible as the overall management of the 
participants depended on their own 
personal choice as to whether to engage in 
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MMT or enrol in a rehabilitation programme 
and stay NOMT. The dependent variable was 
overall cognitive functioning which was 
assessed at one specific time point through 
administration of the MoCA cognitive tool. 
The independent variable was treatment 
with methadone or not, as an opioid 
replacement. The duration of 
dependence/abstinence/enrolment in 
programme, comorbid dependencies, 
psychiatric treatment, dosage of methadone 
and the duration of methadone 
administration were also variables of 
particular interest. 
The MoCA was administered manually using 
paper and pencil testing. Two versions were 
available, depending on the participant’s 
preference of daily spoken language; an 
English and Maltese version (the latter had 
been already translated and validated in 
another study).31 A score of 26 or more is 
considered normal. The specific cognitive 
domains tested include executive function, 
visuospatial skills, naming, attention, 
language, abstraction, delayed recall and 
orientation. 
 
STATISTICAL ANALYSIS 
SPSS software was used for statistical 
analysis. Initial analyses compared groups on 
demographics with analysis of variance 
(ANOVA) for continuous variables and Chi-
square analyses for categorical variables. 
Any demographic variable that significantly 
varied across groups, was entered into later 
analyses as a covariate. The individual 
cognitive domains tested were compared 
across groups by conducting a one-way 
analysis of variance to examine group (MMT, 
NOMT and HC) effect, followed by post-hoc 
testing with Bonferroni multiple comparison 
analysis. Backward stepwise multivariate 
linear regression was carried out to examine 
the effects of comorbid cocaine dependence 
and different classes of psychiatric 
treatment on cognitive performance and 
thus, determine the presence and account 
for any confounders. The effects of duration 
of dependency/abstinence/methadone 
administration/enrolment in program and 
methadone dosage were examined by 
conducting a correlation analysis. 
In reporting the results, a P value of 0.05 was 
considered as showing statistical 
significance. 
RESULTS 
Participant Demographics 
MMT, NOMT and HC groups did not 
significantly differ with respect to gender (χ2 
=2.167, P=0.338) and district locality (χ2 
=7.197, P=0.707) by Pearson Chi-Square 
analysis. Neither did the three participant 
groups differ with regards to years of 
education (F=1.284, P=0.284) by ANOVA. 
However, they demonstrated significant 
difference with respect to age (F=4.059, 
P=0.022). HC participants were the youngest 
with a mean age of 31.64 ±8.244, followed by 
NOMT participants with a mean age of 34.90 
±6.340 and finally MMT participants being 
the eldest with a mean age of 37.59 ±6.005 
(Table 1). 
Cognitive Domain Performance  
One-way ANOVA was applied to test for any 
significant difference among the participant 
groups (MMT, NOMT and HC) for each 
cognitive domain tested. A significant 
difference was present for visuospatial skills 
and executive function (F=13.621, P= 0.000), 
attention (F=4.777, P=0.012), language 
(F=9.760, P=0.000), abstraction (F=4.813, 
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P=0.011) and delayed recall (F=5.573, 
P=0.006). No significant difference was 
noted among the groups for naming 
(F=1.049, P=0.356) and orientation (F=1.012, 
P=0.369). A highly significant difference was 
observed among the three groups for the 
overall total cognitive score (F=15.782, 
P=0.000). The total cognitive score was 
previously obtained by adding the score of 
each individual cognitive domain for each 
participant in their respective groups. In 
every cognitive domain tested, the NOMT 
group obtained the lowest mean score, 
followed by the MMT group and finally the 
HC with the highest score (Figure 1). 
Post-hoc Bonferroni analysis of multiple 
comparisons (Table 2) was carried out for 
each cognitive domain. The NOMT group 
scored significantly lower than the HC 
(P=0.000) and MMT (P=0.010) group for 
visuospatial / executive function. The 
difference between MMT and HC was not 
significant (P=0.105). 
There was a significant difference between 
the NOMT and HC for attention (P=0.010), 
delayed recall (P=0.006), and abstraction 
(P=0.013) with the NOMT group obtaining 
the least mean score out of all groups. No 
difference was observed between the MMT 
group and HC for attention (P=0.213), 
delayed recall (P=0.077) and abstraction 
(P=1.000) or between MMT and NOMT for 
attention (P=0.644), delayed recall (P=0.987) 
and abstraction (P=0.069). 
HC scored significantly higher than MMT 
(P=0.014) and NOMT group (P=0.000) for 
language. There was no significant 
difference between the MMT and NOMT 
group (P=0.479). 
The HC overall total score was significantly 
higher than both MMT (P=0.007) and NOMT 
group (P=0.000). No statistically significant 
difference existed between MMT and NOMT 
groups (P=0.052).  
 
Multiple Linear Regression Analysis and 
Backward Stepwise Multivariate Linear 
Regression Modelling 
The participants’ age was entered as a 
covariate in a secondary analysis comparing 
each neurocognitive domain performance 
across groups. Multiple linear regression 
analysis was carried out to adjust for age 
since the latter was statistically significantly 
different among the three groups. 
Nonetheless, age was not significant in any 
of the models for each different cognitive 
domain score.   
Backward stepwise multivariate linear 
regression modelling was used to examine 
and account for any possible confounders to 
the MoCA score among the participant 
groups. Comorbid cocaine dependence and 
different classes of psychiatric treatment 
were studied for any effect on cognitive 
performance. No confounder was found to 
be statistically different for the 
neurocognitive score across the three 
groups. 
Correlation Analysis 
The relationships between the individual 
cognitive domain score and duration of 
dependency/abstinence from heroin were 
examined by conducting a correlation 
analysis specific to the MMT and NOMT 
group participants only. The dose and 
duration of methadone administration were 
also correlated exclusively to the MMT 
group, while the duration of enrolment in 
the drug rehab program was correlated with 
each cognitive domain score exclusively to 
the NOMT group. 
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S.D.Standard Deviation, df Degrees of freedom, χ2 Chi-Square,F-statistic 
 
 
 
 
 
 
 
 
 
 
Table 1   Demographic data of Methadone Maintenance Treatment, Not on Methadone 
Treatment and Healthy Control Groups 
Group 
Control 
HC (n=22) 
Opioid Dependent 
MMT           NOMT   
(n=22)             (n=21) 
Statistic Significance P 
Gender 
     Male 
     Female 
 
15(68.2%) 
7 (31.8%) 
 
18 (18.8%) 
4 (18.2%) 
 
13(61.9%) 
8 (38.1%) 
 
 
χ2 2.167, df=2 
 
 
0.338 
District 
     Southern Harbour District 
     Northern Harbour District 
     South Eastern District 
     Western District 
     Northern District 
     N/A (Outside Malta) 
 
14(63.6%) 
4 (18.2%) 
0 (0.0%) 
2 (9.1%) 
2 (9.1%) 
0 (0.0%) 
 
10 (45.5%) 
6 (27.3%) 
2 (9.1%) 
2 (9.1%) 
1 (4.5%) 
1 (4.5%) 
 
10(47.6%) 
4 (0.19%) 
3 (14.3%) 
1 (4.8%) 
1 (4.8%) 
2 (9.5%) 
 
 
 
 
 
χ27.197,df=10 
 
 
 
 
 
0.707 
Education (years: mean ± 
S.D.) 
11.23 ± 2.202 11.91 ± 
1.925 
10.81 ± 
2.657 
F=1.284 0.284 
Age (years: mean ± S.D.) 31.64 ± 8.244 37.59 ± 
6.005 
34.90 ± 
6.340 
F=4.059 0.022 
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Figure 1   A comparison of the percentage mean score for each cognitive domain across the 
groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2   Neurocognitive domain performance of MMT, NOMT and HC participant groups 
 
 
 
Group Control Opioid Dependent Statistic Significance 
P 
Paired 
Comparison 
 HC MMT NOMT    
  Mean ± S.D.    
ANOVA       
Visuospatial/Executive 4.73 ± 0.550 4.14 ± 0.889 3.29 ± 1.189 F=13,621 0.000 B,C 
Naming 3.00 ± 0.000 3.00 ± 0.000 2.95 ± 0.218 F=1.049 0.356 _ 
Attention 5.41 ± 0.734 4.77 ± 1.193 4.33 ± 1.426 F=4.777 0.012 B 
Language 2.23 ± 0.752 1.50 ± 0.913 1.14 ± 0.793 F=9.760 0.000 A,B 
Abstraction 1.91 ± 0.294 1.82 ± 0.501 1.48 ± 0.602 F=4.813 0.011 B 
Delayed Recall 3.23 ± 0.973 2.27 ± 1.486 1.86 ± 1.6221 F=5.573 0.006 B 
Orientation 5.86 ± 0.351 5.68 ± 0.477 5.67 ± 0.658 F=1.012 0.369 _ 
Total Score 26.36 ± 1.677 23.18 ± 3.375 20.71 ± 4.361 F=15.782 0.000 A,B 
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Figure 2   Scatterplot showing the variability of Language score with Duration of Dependency  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3   Scatterplot showing the variability of Abstraction score with Duration of Abstinence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The duration of dependency was noted to be 
negatively correlated with the language 
domain for both MMT and NOMT groups 
(P=0.012) (Figure 2). An analysis of the 
language domain as the dependent variable 
with group, as the between-subject factor 
(MMT and NOMT) and duration of dependency 
as covariate, did not reveal a statistically 
significant effect of group (P=0.437). The 
covariate of duration of dependency remained 
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statistically significant (P=0.017). Thus, the 
difference in language between MMT and 
NOMT groups is not significant in the presence 
of the duration of dependency. The duration of 
dependency was not significantly correlated to 
any other cognitive domain, nor was it 
correlated to the overall total score (P=0.140). 
The duration of abstinence was noted to be 
positively correlated with the abstraction 
domain for both MMT and NOMT groups 
(P=0.50) (Figure 3). An analysis of the 
abstraction domain as the dependent variable 
with group, as the between-subject factor 
(MMT and NOMT) and duration of abstinence 
as covariate, did not reveal a statistically 
significant effect of group (P=0.251). The 
covariate of duration of abstinence from 
heroin did not remain statistically significant 
(P=0.258). The duration of abstinence was not 
significantly correlated to any other cognitive 
domain, nor was it correlated to the overall 
total score (P=0.082).  
No significant correlation was observed for 
dose and duration of methadone 
administration with each cognitive domain 
tested and with the overall total score for the 
MMT group (P=0.585 and P=0.897 
respectively). Similarly, no significant 
correlation was noted for the duration of 
enrolment in the drug rehab program with 
each cognitive domain tested and with the 
overall total score for the NOMT group 
(P=0.529). 
 
DISCUSSION 
Individuals with no history of SUD tend to 
exhibit superior cognitive functioning 
compared to those who abuse opioids and 
other psychoactive substances, as highlighted 
in this study and elsewhere. The present 
research sheds further light on factors that can 
affect cognitive function in an already 
impaired group. 
Individuals who are stable on methadone 
appear to have significant problems primarily 
in the language domain compared to controls 
whilst those who are weaned off methadone 
exhibit impairments in multiple cognitive 
domains, in particular visuospatial and 
executive function, attention, language, 
abstraction and delayed recall. Visuospatial 
impairment was previously reported in an 
NOMT group in a similar comparison.16 
Another study highlighted enhanced attention 
in the MMT group, consistent with this study.18 
Executive functions such as impulse control, 
verbal learning and memory, visuospatial 
memory, and psychomotor speed, were also 
previously shown to be superior in the MMT 
group.19 
Though the significant language domain 
impairment of the MMT group in this study 
influenced the total MoCA score leading to a 
minimal overall difference compared to the 
NOMT group, methadone stabilisation appears 
to offer some sort of stabilisation, if not 
recovery, especially with regards to 
visuospatial abilities and executive function. 
Our findings did not show significant 
differences between the majority of the 
cognitive domains tested in the MMT and the 
HC groups. This was not the case when the HC 
and NOMT groups were compared, with 
contrasting levels of cognitive function in 
multiple domains.  
Figure 1 clearly illustrates a typical crescendo 
pattern, with the mean score for each 
cognitive domain of the NOMT group being 
the lowest, reflecting poorest cognitive 
function, while the HC scoring the highest. The 
MMT group mean scores appear to lie in 
between the other two groups, highlighting 
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the fact that methadone may promote 
neurocognitive recovery in individuals who had 
previously been dependent on heroin. This 
contrasts markedly with the findings of a study 
where the abstinent group reportedly had an 
overall better cognitive performance than the 
MMT group.15 However, the researchers 
admittedly included subjects with current illicit 
drug use and performed retrospective 
comparisons, increasing the effect of 
confounders.  
The present study and others have sustained 
the view that individuals with OD who are 
retained on MMT seem to exhibit better 
cognitive function compared to those who 
underwent detoxification, at least partially 
explaining the superiority of MMT over 
interventions with a drug-free ideology. The 
enhanced cognitive stability offered by MMT 
can come in handy when such patients are 
subjected to the challenges of psychosocial 
interventions such as cognitive behavioural 
therapy. Individuals with OD have an increased 
risk of emotional dysregulation primarily as a 
result of impaired cognitive reappraisal.13-14 In 
a study comparing the effects of MMT and CBT 
on cognitive emotional regulation, both were 
shown to be significantly effective and the 
authors suspect this may be one of the 
underlying mechanisms of MMT which 
instigates improved cognitive function.32 
This study also revealed a strong correlation 
between the duration of the OD career with 
the degree of impairment in the language 
domain; methadone did not seem to stabilise 
cognition in subjects who accumulated more 
brain changes over a longer exposure to 
opioids. This justifies the Bonferroni analysis 
for the language domain where both MMT and 
NOMT groups scored significantly lower than 
the HC. One possible interpretation of this 
finding is that a ceiling effect exists in our 
drug-using participants due to the severity of 
OD that may have masked any differential 
effect of chronic opiate use on cognitive 
function. 
The results of this study have important 
implications in management. Individuals who 
are on methadone are frequently stigmatised 
and encouraged to come off methadone at a 
stage when risk of relapse is still significant. In 
particular, there is a blanket approach to those 
planning to join a residential drug 
rehabilitation programme. For some, 
methadone detoxification prior to rehab not 
only lowers their ability to cope with the 
challenges of the programme due to a possible 
deterioration in executive function, but 
exposes them to associated risks. Cognitive 
function plays a key role in treatment efficacy. 
Prohibiting proven medical treatments at all 
costs in rehab programmes may be limiting the 
effectiveness of the same programmes apart 
from depriving individuals with complex needs 
from making progress through their full 
cognitive potential. In addition, specific 
interventions targeting neurocognitive 
dysfunction should become an essential 
component of all interventions in the addiction 
field.  
Limitations of this current study include a 
small population size, a demographic 
difference of age among the group 
participants and illicit substance use history 
measures have been collected based on the 
participants’ self-reports. Routine urine 
testing does not identify all abused illicit 
drugs, such as the widely consumed synthetic 
cannabis receptor agonists. A cross-sectional 
study was performed as opposed to a 
longitudinal design with MMT patients pre and 
post methadone detoxification. It is also fairly 
well recognised that opiate addicts have 
abused a variety of illicit substances which are 
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usually under-reported. It is therefore, 
possible that any type of illicit substance might 
lead to cognitive deficits due to a direct toxic 
insult to the brain. In addition, the unhealthy 
lifestyle associated with severe OD might 
include malnutrition, exposure to violence or 
infections which could indirectly contribute to 
a decreased cognitive performance. We have 
specifically asked all our participants recruited 
in this study for any history of head trauma or 
probed for medical conditions which could 
affect cognition. 
This study is unique in rigorous exclusion of 
comorbid Axis I and Axis II disorders which 
could affect cognitive function. In addition, 
abstinence was ensured by repeated screening 
for any illicit substance and automatic 
exclusion of individuals who failed to submit a 
urine sample or who have abused any illicit 
substance in the last month. All interviews 
were conducted by the same clinician to 
minimise the chances of observer or 
systematic bias. 
 
 
CONCLUSION 
Despite its limitations, our study addresses the 
issue of cognitive impairment in rigorously 
screened abstinent heroin addicts. Our results 
indicate that methadone offers a better level 
of cognitive function compared to premature 
opioid substitute cessation. Given the extent 
of opioid addiction in the community, MMT 
provides public health benefits by augmenting 
cognitive performance and social function in 
former OD individuals. It can ensure 
compliance with treatment plans, reduce 
relapse rates and risky behaviours in heroin 
addicts, thus fostering productivity and 
resumption of important responsibilities. It 
highlights the importance of performing 
neuropsychological assessments as an aspect 
of patient evaluation in drug rehab 
programmes and other venues of care, thus, 
identifying and acknowledging significant 
cognitive impairment, and providing 
appropriate care packages.  
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